Peroxiredoxin 6 serum levels and risk of neutropenic infections in diffuse large B-cell lymphoma
Kari, Esa Jaakko Mikael; Kuusisto, Milla Elvi Linnea; Böhm, Jan; Haapasaari, Kirsi-Maria; Teppo, Hanna-Riikka; Karihtala, Peeter; Hakalahti, Anna; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi
KARI, E. J. M., KUUSISTO, M. E. L., BÖHM, J., HAAPASAARI, K.-M., TEPPO, H.-R., KARIHTALA, P., HAKALAHTI, A., TURPEENNIEMI-HUJANEN, T., & KUITTINEN, O. (2019). Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma. Anticancer Research, 39(9), 4925–4931. https://doi.org/10.21873/anticanres.13680
Copyright © 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Published in this repository with the kind permission of the publisher.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2020040110050
Tiivistelmä
Abstract
Background/Aim:Diffuse large B‐cell lymphoma (DLBCL) is an aggressive malignancy where antioxidant enzyme peroxiredoxin 6 (Prx6) has previously been associated with adverse outcomes. Its systemic effects in DLBCL are unknown.
Materials and methods:This study included 53 patients with DLBCL, five patients with primary central nervous system lymphoma (PCNSL) and 20 healthy controls. The expression of Prx6 was evaluated immunohistochemically in DLBCL tissue samples and compared to its expression in blood serum.
Results:Prx6 expression was the highest in healthy controls, followed by DLBCL patients and PCNSL patients. Febrile neutropenic infection after the first treatment course was associated with low pre-treatment Prx6 serum levels (<14 ng/ml) (p=0.025, OR=8.615, 95% confidence interval=1.032‐71.933). Serum levels of Prx6 recovered after treatment (p=0.006).
Conclusion:Patients with low Prx6 levels might be more prone to treatment‐related adverse effects through elevated levels of oxidative stress.
Kokoelmat
- Avoin saatavuus [38404]